Catapult Capital Management’s GSK GSK Stock Holding History

Catapult Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$1.62M	Buy	+33,629	New	+$1.75M	0.61%	55

Other funds holding GSK

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Catapult Capital Management's GSK Position: Q3 2015 in Review

Catapult Capital Management opened a new position in GSK (GSK) in Q3 2015: 33,629 shares worth $1.62M. The stake represents 0.61% of the portfolio and ranks #55 among its holdings.

707 funds tracked by Wall St. Rank hold GSK as of Q3 2015.

Catapult Capital Management held 33,629 shares of GSK worth $1.62M as of Q3 2015.
GSK was a new Catapult Capital Management position in Q3 2015.
GSK made up 0.61% of Catapult Capital Management's portfolio in Q3 2015, its #55 holding.
707 funds tracked by Wall St. Rank held GSK as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.